David Reeser is one of the millions of Americans whose life has been changed by the ever-evolving, fast-growing epidemic of ...

Radiopharmaceuticals, once a very niche drug class, are now on the brink of transforming cancer treatment and diagnostics, and North Carolina is at the heart of this change. These radioactive drugs ...

Charles E. Hamner, Jr., Ph.D., a former president and CEO of the North Carolina Biotechnology Center and a longtime advocate for life sciences in the state, has received the 2024 High Flyer Champion ...

Research Triangle Park-based Opus Genetics, a clinical-stage gene therapy company devoted to treating inherited retinal diseases, has been acquired by a small ophthalmic biopharmaceutical firm with ...

The Triangle is known as a hotbed for innovation, thanks in large part to the partnerships between multiple stakeholders, including universities, investors and ecosystem support organizations. In that ...

Ad Astra Diagnostics (AAD) of Morrisville has been awarded a $5 million federal contract for the development of an improved diagnostic system to deliver faster complete blood count (CBC) test results ...

Jude Samulski calls genome editing “the next wave of technology to feed the world.” Samulski contributed $3 million to create the Roberts and Mikhail Distinguished Chair in Plant Genome Editing, an ...

Shanghai-based cancer immunotherapy innovator CARsgen joined the surge of gene- and cell-based therapy companies setting up shop in North Carolina today when it announced plans to invest $157 million ...

With North Carolina’s biopharmaceutical manufacturing industry continuing to expand, two college-based programs are working to stay ahead of the growth by preparing students for promising careers in ...

If you’re not hip to having hip replacement surgery, CytexOrtho may soon have a different and – for some patients – better solution. The Durham-based startup is developing an innovative new implant ...

AgBiome has developed and commercialized its biological agricultural products by striking up alliances with larger companies in the industry. Now the company has three more partnerships, two that will ...

Enzyvant Therapeutics, Inc. and Altavant Sciences, Inc., both wholly owned subsidiaries of the global biopharmaceutical giant Sumitovant Biopharma Ltd., today announced a merger to form a North ...